195 related articles for article (PubMed ID: 15540985)
1. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
Sánchez-Arévalo Lobo VJ; Aceves Luquero CI; Alvarez-Vallina L; Tipping AJ; Viniegra JG; Hernández Losa J; Parada Cobo C; Galán Moya EM; Gayoso Cruz J; Melo JV; Ramón y Cajal S; Sánchez-Prieto R
Biochem J; 2005 Apr; 387(Pt 1):231-8. PubMed ID: 15540985
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
3. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
4. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
[TBL] [Abstract][Full Text] [Related]
5. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.
Galan-Moya EM; Hernandez-Losa J; Aceves Luquero CI; de la Cruz-Morcillo MA; Ramírez-Castillejo C; Callejas-Valera JL; Arriaga A; Aranburo AF; Ramón y Cajal S; Silvio Gutkind J; Sánchez-Prieto R
Int J Cancer; 2008 Jan; 122(2):289-97. PubMed ID: 17893873
[TBL] [Abstract][Full Text] [Related]
6. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
Dumka D; Puri P; Carayol N; Lumby C; Balachandran H; Schuster K; Verma AK; Terada LS; Platanias LC; Parmar S
Leuk Lymphoma; 2009 Dec; 50(12):2017-29. PubMed ID: 19672773
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
8. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
9. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
Nica AF; Tsao CC; Watt JC; Jiffar T; Kurinna S; Jurasz P; Konopleva M; Andreeff M; Radomski MW; Ruvolo PP
Cell Cycle; 2008 Nov; 7(21):3362-70. PubMed ID: 18948750
[TBL] [Abstract][Full Text] [Related]
10. Regulation of p73 by c-Abl through the p38 MAP kinase pathway.
Sanchez-Prieto R; Sanchez-Arevalo VJ; Servitja JM; Gutkind JS
Oncogene; 2002 Jan; 21(6):974-9. PubMed ID: 11840343
[TBL] [Abstract][Full Text] [Related]
11. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
[TBL] [Abstract][Full Text] [Related]
12. Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
Iotti G; Ferrari-Amorotti G; Rosafio C; Corradini F; Lidonnici MR; Ronchetti M; Bardini M; Zhang Y; Martinez R; Blasi F; Calabretta B
Oncogene; 2007 May; 26(24):3482-91. PubMed ID: 17160016
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
14. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
16. Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.
Goetz AW; van der Kuip H; Maya R; Oren M; Aulitzky WE
Cancer Res; 2001 Oct; 61(20):7635-41. PubMed ID: 11606405
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Yu C; Dai Y; Dent P; Grant S
Cancer Biol Ther; 2002; 1(6):674-82. PubMed ID: 12642693
[TBL] [Abstract][Full Text] [Related]
18. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine.
Raina D; Mishra N; Kumar S; Kharbanda S; Saxena S; Kufe D
Mol Pharmacol; 2002 Jun; 61(6):1489-95. PubMed ID: 12021410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]